Phase 3 ACHIEVE-1 trial results for orforglipron, as discussed by Rosenstock and colleagues, demonstrated that this once-daily oral small molecule GLP-1 achieved statistically significant reductions in HbA1c (1.3% to 1.6% from a baseline of 8.0%) compared to placebo in adults with type 2 diabetes
McMurray JJV, Solomon SD, Inzucchi SE, Kber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Blohlvek J, Bhm M, Chiang C-E, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukt A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, OMeara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjstrand M, Langkilde A-M
Keep reading for three example scenarios to help you make what can occasionally be a challenging decision (adapted from this post by WebPTs Kylie McKee)
The initial research in the eld was focused on the exploration of the enzymatic and fermentation production methods of glutathione synthesis, which have been reviewed in detail by Li et al
A case includes 12 cans, 12 fl oz (355 mL) each
Physiology & Performance Limiting Factors 00:10:35 Sponsor: AG1 00:12:30 Muscular Endurance, Protocol, Concentric Movements, Mitochondria 00:19:10 Sponsors: LMNT & Eight Sleep 00:22:00 Long-Duration Endurance, Efficiency, Mitochondria, Capillaries 00:25:54 High-Intensity Interval Training (HIIT), Anaerobic Endurance, Protocol 00:32:33 High-Intensity Aerobic Endurance, Adaptations 00:35:30 Sponsor: Function 00:37:26 Brain & Body Adaptations, Heart 00:40:40 Hydration, Tool: Galpin Equation 00:42:21 Supplements, Stimulants, Magnesium Malate 00:43:11 Recap & Key Takeaways Disclaimer & Disclosures Day 263 Tools for Overcoming Substance & Behavioral Addictions | Ryan Soave My guest is Ryan Soave, LMHC, a leading expert in addiction recovery with extensive experience helping people heal from all types of substance and behavioral dependencies
/images/2025/03/06/80a97023-8cda-4f9b-9f34-acfd82496b14.png)
